
Geron (GERN) Stock Forecast & Price Target
Geron (GERN) Analyst Ratings
Bulls say
Geron Corp's approval of Rytelo in the European Union is anticipated to enhance revenue streams starting in 2026, with additional approvals expected within the first half of 2025, which could further complement the drug's U.S. launch. The potential for Rytelo to address relapsed/refractory myelofibrosis is believed to potentially double its commercial opportunity, particularly given its benefits in reducing transfusion burdens for patients despite associated risks. The company is focused on expanding physician prescribing and patient uptake through targeted education efforts, positioning itself for robust sales growth in newly identified market segments.
Bears say
Geron Corp's recent financial performance indicates troubling trends, particularly the slowdown in revenue growth due to the underwhelming uptake of Rytelo among second-line patients, which is vital for the drug's market expansion. Management's acknowledgment of flat revenue trends and a shift in key trial results to the second half of 2026 suggests a lack of near-term catalysts that could support recovery and growth. Additionally, lowered expectations for Rytelo's peak sales and potential risks related to clinical efficacy, market competition, and regulatory hurdles further contribute to a cautious outlook on the company's financial viability.
This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.
Geron (GERN) Analyst Forecast & Price Prediction
Start investing in Geron (GERN)
Order type
Buy in
Order amount
Est. shares
0 shares